Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.72
+0.52 (0.84%)
At close: Dec 19, 2025, 4:00 PM EST
62.05
-0.67 (-1.07%)
After-hours: Dec 19, 2025, 7:59 PM EST
Cytokinetics Revenue
Cytokinetics had revenue of $1.94M in the quarter ending September 30, 2025, with 318.14% growth. This brings the company's revenue in the last twelve months to $9.41M, up 323.84% year-over-year. In the year 2024, Cytokinetics had annual revenue of $18.47M with 145.34% growth.
Revenue (ttm)
$9.41M
Revenue Growth
+323.84%
P/S Ratio
85.59
Revenue / Employee
$175,122
Employees
498
Market Cap
7.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.47M | 10.94M | 145.34% |
| Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
| Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
| Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
| Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
| Dec 31, 2019 | 26.87M | -4.63M | -14.71% |
| Dec 31, 2018 | 31.50M | 18.13M | 135.64% |
| Dec 31, 2017 | 13.37M | -93.04M | -87.44% |
| Dec 31, 2016 | 106.41M | 77.75M | 271.30% |
| Dec 31, 2015 | 28.66M | -18.28M | -38.95% |
| Dec 31, 2014 | 46.94M | 16.29M | 53.16% |
| Dec 31, 2013 | 30.65M | 23.09M | 305.45% |
| Dec 31, 2012 | 7.56M | 3.56M | 88.98% |
| Dec 31, 2011 | 4.00M | 1.42M | 55.22% |
| Dec 31, 2010 | 2.58M | -78.96M | -96.84% |
| Dec 31, 2009 | 81.54M | 69.12M | 556.51% |
| Dec 31, 2008 | 12.42M | -1.20M | -8.82% |
| Dec 31, 2007 | 13.62M | 10.50M | 335.63% |
| Dec 31, 2006 | 3.13M | -5.79M | -64.91% |
| Dec 31, 2005 | 8.91M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CYTK News
- 23 hours ago - US FDA approves Cytokinetics' heart disease drug - Reuters
- 23 hours ago - Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms - GlobeNewsWire
- 3 days ago - Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy - GlobeNewsWire
- 3 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 8 days ago - Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy - GlobeNewsWire
- 16 days ago - 3 Potential Mid-Cap Biotech Buyout Targets In 2026 - Seeking Alpha
- 4 weeks ago - Cytokinetics: A Heavily Mispriced Cardiovascular Platform - Seeking Alpha
- 4 weeks ago - Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy - GlobeNewsWire